CCR5 is a potential therapeutic target for cancer.

Hemmatazad, Hossein; Berger, Martin D. (2021). CCR5 is a potential therapeutic target for cancer. Expert opinion on therapeutic targets, 25(4), pp. 311-327. Taylor & Francis 10.1080/14728222.2021.1902505

Full text not available from this repository. (Request a copy)

INTRODUCTION

Chemokines and their cognate receptors play a major role in modulating inflammatory responses. Depending on their ligand binding, chemokine receptors can stimulate both immune activating and inhibitory signaling pathways. The CC chemokine receptor 5 (CCR5) promotes immune responses by recruiting immune cells to the sites of inflammation/tumor, and is involved in stimulating tumor cell proliferation, invasion and migration through various mechanisms. Moreover, CCR5 also contributes to an immune-suppressive tumor microenvironment by recruiting regulatory T cells and myeloid-derived suppressor cells facilitating tumor development and progression. In summary, cells expressing CCR5 modulate immune response and tumor progression. Expression of CCR5 is increased in various malignancies and associated with poor outcome. Experimental data show promising efficacy signals with CCR5 antagonists in preclinical tumor models. Therefore, CCR5 has been recognized as a potential therapeutic target for cancer.

AREAS COVERED

In this review, we focus on the role of CCR5 in cancer progression and discuss its impact and potential as a therapeutic target for cancer.

EXPERT OPINION

Beyond immune-checkpoint inhibitors, potentially synergistic immune-modulatory drugs such as CCR5 antagonists are a promising approach to enlarge our treatment armamentarium against cancer.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Radiation Oncology

UniBE Contributor:

Hemmatazad, Hossein and Berger, Martin Dave

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1744-7631

Publisher:

Taylor & Francis

Language:

English

Submitter:

Beatrice Scheidegger

Date Deposited:

29 Apr 2021 10:33

Last Modified:

17 Jun 2021 01:33

Publisher DOI:

10.1080/14728222.2021.1902505

PubMed ID:

33719836

Uncontrolled Keywords:

CCR5 cancer chemokine chemokine receptors therapeutic target

URI:

https://boris.unibe.ch/id/eprint/154570

Actions (login required)

Edit item Edit item
Provide Feedback